Regeneron has declined 26.5% over this time frame, while the broader S&P 500 Index has soared 20.7%. Moreover, the stock is down 1.7% on a YTD basis, compared to SPX’s 2.2% gain during the same ...

Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1. The Significance of Analyst Ratings Explained ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Bernstein cuts Regeneron stock price target to $1,000, keeps Outperform. 3mo. ... REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

Regeneron Pharmaceuticals, Inc. (REGN) is a leading American biotechnology company headquartered in Tarrytown, New York. Valued at $52.9 billion by market cap, the company focuses on discovering ...

On Tuesday, UBS analysts reaffirmed their Neutral rating for Regeneron Pharma stock (NASDAQ: NASDAQ: REGN), maintaining a price target of $633.00.The decision follows recent developments in ...

This was the stock's fourth consecutive day of gains.